Slow-release injecta containing amino glucosides antibiotics and use thereof
A technology of sustained-release injections and aminoglycosides, applied in the field of sustained-release injections, which can solve the problems of increased dose side effects, difficulty in obtaining effective bactericidal concentrations, etc., and achieve the effects of reducing the course of treatment, facilitating drug application, and reducing costs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0098] Put 90, 90 and 80 mg of polyphenylpropane (p-carboxyphenylpropane (p-CPP): sebacic acid (SA) at 20:80) copolymers into (A), (B) and (C) three In two containers, add 100 milliliters of dichloromethane to each, after dissolving and mixing, add 10 mg arbekacin, 10 mg amikacin, and 20 mg asmitacin respectively, shake them up again, and use spray-drying method to prepare the mixture containing 10% arbekacin, 10% amikacin and 20% asmitacin microspheres for injection. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 350cp-550cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 7-14 days, and the drug release time in mice subcutaneous is about 15-25 days.
Embodiment 2
[0100] The method steps of being processed into sustained-release injections are the same as in Example 1, but the difference is that the antibacterial active ingredients and their weight percentages are: 2-50% paromomycin, dibekacin, ribomycin, carbane Namycin, kanamycin B, amikacin B, dideoxykanamycin B, amikacin, rivamycin, tilmicosin, netilmicin , Tobramycin, Sisomicin, Etimicin, Penicillin A, Gentamicin, Vertimicin, Doxycycline, Small Normicin, Isopamicin, Isopamicin, Tylosin, Virginmycin, Salinomycin, Flavomycin, Tylomycin, Telosin, Virginmycin, Hiduramycin, Sisomycin, Lidamycin, Fluoride Benicol, rifaximin, or daptomycin.
Embodiment 3
[0102] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 10,000 into three containers (A), (B) and (C) respectively, and then add 100 ml of dichloromethane to each, dissolve and mix well , add 30mg paromomycin, 30mg dibekacin, 30mg ribomycin respectively in three containers, shake up again and use spray-drying method to prepare containing 30% paromomycin, 30% dibekacin, 30 % Ribomycin Microspheres for Injection. The dried microspheres are suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 500cp-650cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 7-15 days, and the drug release time in mice subcutaneous is about 15-25 days.
PUM
Property | Measurement | Unit |
---|---|---|
Viscosity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com